PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta” or the “Company”) (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024.
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed...